Brookline Capital Markets Reiterates X4 Pharmaceuticals (XFOR) at Buy with $13 PT, Sees Peak Mavorixafor Sales of $450.9M
Tweet Send to a Friend
Brookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $13.00 price target on X4 Pharmaceuticals (NASDAQ: XFOR) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
